Bharat Biotech adds 200 million dose per annum Covaxin capacity

The company said the quick ramp up of additional manufacturing capacities for Covaxin was done at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma

Premium

BS Reporter Mumbai

1 min read Last Updated : May 21 2021 | 12:31 AM IST

Bharat Biotech said on Thursday that production volumes have been ramped up by an additional 200 million doses at Ankleshwar, Gujarat. Product availability at Ankleshwar to commence from Q4 FY2022 (Jan-March).

The company said the quick ramp up of additional manufacturing capacities for Covaxin was done at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech.

"The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety," it said.

Topics : Coronavirus Bharat Biotech Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in